Augmedix (AUGX) Stock Forecast, Price Target & Predictions
AUGX Stock Forecast
Augmedix stock forecast is as follows: an average price target of $2.67 (represents a 15.58% upside from AUGX’s last price of $2.31) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AUGX Price Target
The average price target for Augmedix (AUGX) is $2.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.50 to $1.50. This represents a potential 15.58% upside from AUGX's last price of $2.31.
AUGX Analyst Ratings
According to 5 Wall Street analysts, Augmedix's rating consensus is 'Hold'. The analyst rating breakdown for AUGX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Augmedix Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Brooks O'Neil | Loop Capital Markets | $3.50 | $1.15 | 204.35% | 51.52% |
| May 14, 2024 | Yuan Zhi | B.Riley Financial | $3.00 | $2.34 | 28.21% | 29.87% |
| May 14, 2024 | Elizabeth Anderson | Evercore ISI | $1.50 | $2.34 | -35.90% | -35.06% |
| Apr 09, 2024 | Elizabeth Anderson | Evercore ISI | $5.00 | $4.02 | 24.38% | 116.45% |
| Apr 03, 2024 | Yuan Zhi | B.Riley Financial | $5.50 | $4.02 | 36.82% | 138.10% |
| Mar 19, 2024 | Elizabeth Anderson | Evercore ISI | $4.50 | $3.96 | 13.64% | 94.81% |
The latest Augmedix stock forecast, released on May 14, 2024 by Brooks O'Neil from Loop Capital Markets, set a price target of $3.50, which represents a 204.35% increase from the stock price at the time of the forecast ($1.15), and a 51.52% increase from AUGX last price ($2.31).
Augmedix Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 6 |
| Avg Price Target | - | - | $3.83 |
| Last Closing Price | $2.31 | $2.31 | $2.31 |
| Upside/Downside | -100.00% | -100.00% | 65.80% |
In the current month, the average price target of Augmedix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Augmedix's last price of $2.31. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 19, 2024 | B. Riley | - | Neutral | Downgrade |
| Jul 19, 2024 | William Blair | - | Market Perform | Downgrade |
| Jun 04, 2024 | Lake Street | Buy | Buy | Hold |
| May 14, 2024 | Lake Street | Buy | Buy | Hold |
| Apr 09, 2024 | Evercore ISI | - | Outperform | Upgrade |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Augmedix's last stock rating was published by B. Riley on Jul 19, 2024. The company Downgrade its AUGX rating from "null" to "Neutral".
Augmedix Financial Forecast
Augmedix Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $12.68M | $11.77M | - | $9.63M | $8.75M | $7.86M | $7.33M | $6.99M | $6.58M | $5.63M | $5.17M |
| Avg Forecast | $17.70M | $16.80M | $15.50M | $14.60M | $12.87M | $12.95M | $13.64M | $13.36M | $12.46M | $11.43M | $10.37M | $9.39M | $8.57M | $7.76M | $7.33M | $6.91M | $6.40M | $5.61M | $5.18M |
| High Forecast | $18.16M | $17.24M | $15.91M | $14.98M | $13.21M | $13.07M | $13.99M | $13.71M | $12.79M | $11.73M | $10.64M | $9.64M | $8.79M | $7.96M | $7.46M | $7.03M | $6.51M | $5.71M | $5.27M |
| Low Forecast | $17.07M | $16.20M | $14.95M | $14.08M | $12.42M | $12.82M | $13.15M | $12.89M | $12.02M | $11.02M | $10.00M | $9.06M | $8.26M | $7.48M | $7.17M | $6.75M | $6.25M | $5.48M | $5.06M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.03% | - | 1.03% | 1.02% | 1.01% | 1.00% | 1.01% | 1.03% | 1.00% | 1.00% |
Augmedix's average Quarter revenue forecast for Mar 24 based on 1 analysts is $13.36M, with a low forecast of $12.89M, and a high forecast of $13.71M. AUGX's average Quarter revenue forecast represents a 5.38% increase compared to the company's last Quarter revenue of $12.68M (Dec 23).
Augmedix EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.04M | $-4.40M | - | $-5.09M | $-5.44M | $-5.46M | $-6.05M | $-5.45M | $-5.45M | $-2.11M | $-3.87M |
| Avg Forecast | $-13.30M | $-12.62M | $-11.65M | $-10.97M | $-9.68M | $-9.73M | $-10.25M | $-10.04M | $-9.36M | $-8.59M | $-7.79M | $-7.06M | $-6.44M | $-5.83M | $-5.51M | $-4.28M | $-4.81M | $-1.90M | $-3.89M |
| High Forecast | $-12.83M | $-12.18M | $-11.23M | $-10.58M | $-9.33M | $-9.64M | $-9.88M | $-9.68M | $-9.03M | $-8.28M | $-7.52M | $-6.81M | $-6.21M | $-5.62M | $-5.38M | $-3.43M | $-4.70M | $-1.52M | $-3.80M |
| Low Forecast | $-13.65M | $-12.96M | $-11.95M | $-11.26M | $-9.93M | $-9.82M | $-10.52M | $-10.30M | $-9.61M | $-8.81M | $-8.00M | $-7.24M | $-6.61M | $-5.98M | $-5.61M | $-5.14M | $-4.89M | $-2.28M | $-3.96M |
| Surprise % | - | - | - | - | - | - | - | - | 0.43% | 0.51% | - | 0.72% | 0.85% | 0.94% | 1.10% | 1.27% | 1.13% | 1.11% | 0.99% |
undefined analysts predict AUGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Augmedix's previous annual EBITDA (undefined) of $NaN.
Augmedix Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-4.49M | $-4.41M | - | $-5.27M | $-5.76M | $-5.52M | $-8.84M | $-6.43M | $-6.08M | $-2.86M | $-4.64M |
| Avg Forecast | $-4.80M | $-5.87M | $-6.41M | $-6.94M | $-7.47M | $-7.21M | $-7.12M | $-6.94M | $-5.21M | $-6.14M | $-6.94M | $-8.01M | $-8.34M | $-9.21M | $-8.41M | $-5.09M | $-8.28M | $-2.57M | $-10.14M |
| High Forecast | $-4.58M | $-5.60M | $-6.11M | $-6.62M | $-7.13M | $-6.87M | $-6.79M | $-6.62M | $-4.97M | $-5.86M | $-6.62M | $-7.64M | $-7.95M | $-8.78M | $-8.16M | $-4.07M | $-8.03M | $-2.06M | $-9.85M |
| Low Forecast | $-4.97M | $-6.07M | $-6.62M | $-7.18M | $-7.73M | $-7.45M | $-7.36M | $-7.18M | $-5.38M | $-6.35M | $-7.18M | $-8.28M | $-8.62M | $-9.52M | $-8.60M | $-6.11M | $-8.46M | $-3.09M | $-10.38M |
| Surprise % | - | - | - | - | - | - | - | - | 0.86% | 0.72% | - | 0.66% | 0.69% | 0.60% | 1.05% | 1.26% | 0.73% | 1.11% | 0.46% |
Augmedix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Augmedix SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $7.65M | $7.30M | - | $6.77M | $6.88M | $6.44M | $6.60M | $6.28M | $-7.92M | $5.39M | $4.95M |
| Avg Forecast | $15.74M | $14.94M | $13.79M | $12.99M | $11.45M | $11.52M | $12.13M | $11.89M | $11.08M | $10.16M | $9.23M | $8.35M | $7.62M | $6.90M | $6.52M | $5.38M | $5.69M | $4.86M | $4.61M |
| High Forecast | $16.16M | $15.34M | $14.15M | $13.33M | $11.75M | $11.62M | $12.45M | $12.20M | $11.37M | $10.43M | $9.47M | $8.57M | $7.82M | $7.08M | $6.64M | $6.46M | $5.79M | $5.83M | $4.69M |
| Low Forecast | $15.19M | $14.41M | $13.30M | $12.53M | $11.05M | $11.41M | $11.70M | $11.46M | $10.69M | $9.80M | $8.90M | $8.06M | $7.35M | $6.65M | $6.37M | $4.30M | $5.56M | $3.88M | $4.50M |
| Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.72% | - | 0.81% | 0.90% | 0.93% | 1.01% | 1.17% | -1.39% | 1.11% | 1.07% |
Augmedix's average Quarter SG&A projection for Mar 24 is $11.89M, based on 1 Wall Street analysts, with a range of $11.46M to $12.20M. The forecast indicates a 55.30% rise compared to AUGX last annual SG&A of $7.65M (Dec 23).
Augmedix EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.09 | $-0.10 | - | $-0.14 | $-0.15 | $-0.15 | $-0.24 | $-0.17 | $-0.16 | $-0.11 | $-0.17 |
| Avg Forecast | $-0.09 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.14 | $-0.13 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.15 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.15 | $-0.14 | $-0.19 |
| High Forecast | $-0.09 | $-0.10 | $-0.11 | $-0.12 | $-0.13 | $-0.13 | $-0.13 | $-0.12 | $-0.09 | $-0.11 | $-0.12 | $-0.14 | $-0.15 | $-0.16 | $-0.15 | $-0.15 | $-0.15 | $-0.14 | $-0.18 |
| Low Forecast | $-0.09 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.14 | $-0.14 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.16 | $-0.16 | $-0.18 | $-0.16 | $-0.16 | $-0.16 | $-0.15 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.84% | - | 0.93% | 0.96% | 0.87% | 1.52% | 1.11% | 1.03% | 0.76% | 0.89% |
According to undefined Wall Street analysts, Augmedix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUGX previous annual EPS of $NaN (undefined).
Augmedix Peer Comparison by Price Target
AUGX Forecast FAQ
Is Augmedix a good buy?
No, according to 5 Wall Street analysts, Augmedix (AUGX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of AUGX's total ratings.
What is AUGX's price target?
Augmedix (AUGX) average price target is $2.67 with a range of $1.5 to $3.5, implying a 15.58% from its last price of $2.31. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Augmedix stock go up soon?
According to Wall Street analysts' prediction for AUGX stock, the company can go up by 15.58% (from the last price of $2.31 to the average price target of $2.67), up by 51.52% based on the highest stock price target, and down by -35.06% based on the lowest stock price target.
Can Augmedix stock reach $3?
AUGX's highest twelve months analyst stock price target of $3.5 supports the claim that Augmedix can reach $3 in the near future.
What are Augmedix's analysts' financial forecasts?
Augmedix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $52.82M (high $53.99M, low $51.28M), average EBITDA is $-39.696M (high $-38.536M, low $-40.571M), average net income is $-28.74M (high $-27.414M, low $-29.72M), average SG&A $46.99M (high $48.02M, low $45.61M), and average EPS is $-0.538 (high $-0.513, low $-0.557). AUGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.6M (high $66.29M, low $62.31M), average EBITDA is $-48.546M (high $-46.823M, low $-49.819M), average net income is $-24.024M (high $-22.915M, low $-24.843M), average SG&A $57.46M (high $58.97M, low $55.42M), and average EPS is $-0.45 (high $-0.429, low $-0.465).
Did the AUGX's actual financial results beat the analysts' financial forecasts?
Based on Augmedix's last annual report (Dec 2023), the company's revenue was $44.86M, beating the average analysts forecast of $43.65M by 2.76%. Apple's EBITDA was $-17.681M, missing the average prediction of $-32.803M by -46.10%. The company's net income was $-19.171M, missing the average estimation of $-26.293M by -27.09%. Apple's SG&A was $29.13M, missing the average forecast of $38.83M by -24.98%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.493 by -10.66%. In terms of the last quarterly report (Dec 2023), Augmedix's revenue was $12.68M, beating the average analysts' forecast of $12.46M by 1.77%. The company's EBITDA was $-4.041M, missing the average prediction of $-9.363M by -56.84%. Augmedix's net income was $-4.491M, missing the average estimation of $-5.205M by -13.72%. The company's SG&A was $7.65M, missing the average forecast of $11.08M by -30.95%. Lastly, the company's EPS was $-0.0916, missing the average prediction of $-0.0975 by -6.05%